

## Advancing Personalized Medicine with Cellular Technologies.

OptiCell, Inc. is a biotech company dedicated to the development of cellular Medicine.


### Our Business

#### Development of Cellular Medicines

We are engaged in the research and development of cellular medicine, which is expected to become a next-generation pharmaceutical product. The underlying technology is a new method (patent pending) that we have independently developed to generate multilineage stem cells from somatic cells.

Our goal is to use this technology to generate progenitor cells for various organs from a patient's own cells and to administer the cells themselves as a drug for practical use in therapies to repair organ function damaged by injury or disease.

To commercialize the system, we intend to establish a medical POC through joint research with universities and medical institutions, and promote medical implementation through a cooperative framework with companies.




### Company Overview

Establishment	Juna, 2023
Founder & CEO	Tasuku Okamoto
Share Capital	5,100,000 Japanese yen
Headquarters	Cross Gate 7 <sup>th</sup> Floor, 1-101-1, Sakuragi-cho, Naka-ku, Yokohama, Kanagawa, Japan 231-0062
Origin of Company Name	“Opticell” was born as a unification of the words “optimize” and “cell” to capture the essence of our goals: the best and most efficient utilization of cells.

# OptiCell's Research & Development

We have developed a novel method (patent pending) to generate Oct4/Nanog positive and multipotent stem cells from somatic cells. For future practical medical applications, we will establish a "direct programming" method using our proprietary CE-peptide as a cell niche factor to induce differentiation into progenitor cells of various organs by reprogramming fibroblasts into stem cells in 3D culture in a manner that does not require gene transfer.



## Message : Our Present and Future

At Opticell, Inc., our philosophy is to contribute to the advancement of personalized medicine. Through the development of cellular medicine technology, we strive to advance personalized medicine that would allow patients to choose the best treatment for their individual needs.

In the future around 2030, we envision the widespread use of personalized cellular medicine, which would allow the patient's own cells to treat damage to bodily functions caused by injury or disease (such as blood disease, immune disorders, and nerve dysfunction). This treatment would be made possible by the new technology we have developed to generate hematopoietic or neural progenitor cells from the patient's own skin cells.

For the cellular medicine we are striving for, not only are innovative technologies and intellectual property important, but also the integrated proteomic and transcriptomic landscape of cell state changes is critical. Similarly, the establishment of a collaborative industry-academia R&D ecosystem is invaluable. We aim to be an R&D startup where all parties create a win-win, mutually beneficial relationship that benefits all three sides: the buyer, the seller, and society.

We look forward to the continued support and cooperation of our stakeholders.

Founder Tasuku Okamoto



Through the development of cellular medicine technology, we will work to promote personalized cellular medicine, allowing patients to choose the best treatment for their individual needs.



We are committed to developing a diverse workforce that fosters innovation and provides an environment where employees can work with peace of mind and a sense of fulfillment.



We will drive innovation in healthcare through collaborative research and development with academia and industry.



In solving medical challenges, we will build an ecosystem of business cooperation between companies and medical research institutions, aiming for a win-win outcome for all parties.